Quick Takeaways
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G for Alto Neuroscience, Inc. Common Stock, $0.0001 par value per share (ANRO).
- Disclosed ownership: 5.9%.
- Date of event: 31 Mar 2025.
ARMISTICE CAPITAL, LLC - 31 Mar 2025 SCHEDULE 13G Report for Alto Neuroscience, Inc. Common Stock, $0.0001 par value per share (ANRO)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- ANRO
- Shares outstanding
- 27,072,758 shares
- Disclosed Ownership
- 1,600,000 shares
- Ownership
- 5.9%
- Form type
- SCHEDULE 13G
- Filing time
- 15 May 2025, 15:05:57 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 18 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"ARMISTICE CAPITAL, LLC disclosed 5.9% ownership in Alto Neuroscience, Inc. Common Stock, $0.0001 par value per share (ANRO) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 15:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 5.9% | 1,600,000 | 0 | 1,600,000 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 5.9% | 1,600,000 | 0 | 1,600,000 | /s/ Steven Boyd | Steven Boyd |